MEK’s founders, Myriam El-Khazen and Selim Dagher, will serve as general manager and executive director, commercial operations, respectively, with overall responsibility for managing INC Research's presence in the region. MEK Consulting will operate under the INC Research name.
"The MENA region offers significant opportunities for new drug development due to its large patient populations, highly qualified medical personnel and increasingly sophisticated regulatory environments," said INC Research chief executive officer Jamie Macdonald. "The acquisition of MEK Consulting provides INC Research's customers with access to this expanding region for biopharmaceutical development and further demonstrates our commitment to connect them to everything they need to conduct their trials."
"We are very excited to be joining INC Research," said Myriam El-Khazen. "We believe this acquisition will bring the MENA region and Southern Europe to a new era in clinical research. This will be advantageous for our customers, the patients in the region and our company. Being part of INC Research, one of the world's leading CROs, will enable us to bring more trials to the region, benefiting patients and health institutions while providing biopharmaceutical companies access to the capabilities and resources of a global organization."